Do you want to read an article? Please log in or register.
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
Multiple Myeloma (MM)
Related content
Multiple Myeloma (MM)
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing
Blood
Schavgoulidze A, Perrot A, Leleu X, Cazaubiel T, Chretien ML, Feugier P, Belhadj K, Manier S, Roussel M, Brechignac S, Orsini Piocelle F, Mohty M, Schiano de Colella JM, Macro M Dr, Adiko D, Dib M, Fontan J, Motard C, Bouscary D, Pascal L, Roland V, Lifermann F, Bakala JA, Montes L, Kennel C, Rey P, Richez V, Keddar F, Frenzel L, Calmettes C, Chaleteix C, Plantier I, Chalayer E, Schmitt A, Roul C, Demarquette H, Cerutti C, Pavageau L, Derrier L, Avet-Loiseau H, Corre J
doi: 10.1182/blood.2025029999
Multiple Myeloma (MM)
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma
Blood Cancer J
Kumar S, Jagannath S, Weisel KC, Rosiñol L, Leleu X, Dimopoulos MA, Kastritis E, Siegel DS, Monge J, Du J, de la Rubia J, Asensi Cantó P, Lee JH, Mateos MV, Puertas B, Gozzetti A, Dytfeld D, Ocio EM, Blade J, Ozaki S, Beksac M, Escalante F, Nagaraj M, Hassan R, Bonar N, Spin P, Shokoohi M, Siddiqui M, Wang D, Hou K, West MED, Hampp C, Green J, Humblet O, Breskin A, Harnett J, Ge W, Sobel RE, Jalbert JJ, Kroog GS, Rodriguez Lorenc K, Ma Q, Durie BGM
doi: 10.1038/s41408-026-01466-2
ASH 2025
Multiple Myeloma (MM)
Elranatamab achieves consistent efficacy in patients with heavily pretreated, high-risk multiple myeloma
Multiple Myeloma (MM)
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma
Blood Cancer J
Hashmi H, Sebastian T, Rajeeve S, Farzana T, Firestone RS, Jurgens EM, Miller KC, Maura F, Lesokhin AM, Tan CR, Shah GL, Korde N, Landau HJ, Merz M, Scordo M, Hassoun H, Maclachlan KH, Shah UA, Hultcrantz ML, Derkach A, Nemirovsky D, Giralt S, Mailankody S, Usmani SZ
doi: 10.1038/s41408-026-01494-y
Multiple Myeloma (MM)
Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data
Br J Haematol
Goel U, Dragomirescu C, Zanwar S, Cassano RC, Cicero KI, Cowan AJ, Banerjee R, Anwer F, Khouri J, Dima D
doi: 10.1111/bjh.70490
Central Nervous System Tumors
Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children's Oncology Group
Neuro Oncol
Mazewski C, Leary SES, Kang G, Li BK, Kellie S, Hayes L, Shaw D, Ho B, Reddy A, Gossett J, Burger PC, Judkins AR, Aridgides P, Geyer JR, Gajjar A, Pollack IF, Fouladi M, Huang A
doi: 10.1093/neuonc/noaf132
Multiple Myeloma (MM)
Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant
Br J Haematol
Venkatesh P, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR, Giri S, Godby KN, Silbermann RW, Mikhail FM, Huls F, Reddy V, Costa LJ, Bal S
doi: 10.1111/bjh.70359
Breast Cancer
Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer
Ann Oncol
Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP, Panelists of the St. Gallen International Breast Cancer Consensus 2025
doi: 10.1016/j.annonc.2025.09.007
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Dingemans AC, Opitz I, Brunelli A, Remon J, Hendriks LEL, Edwards J, Faivre-Finn C, Reguart N, Smit EF, Levy A, Sanchez-Lorente D, Trujillo JC, Filippi AR, Stathopoulos K, Blum TG, Guckenberger M, Popat S, De Angelis R, Hofman P, von der Thüsen J, Hartemink KJ, Petersen RH, Ruffini E, Dickhoff C, Houda I, Prisciandaro E, De Ruysscher D, Derks J, Bahce I, Mariolo A, Besse B, Xenophontos E, Giaj Levra N, van Schil P, Brandão M, Berghmans T
doi: 10.1016/S2213-2600(26)00051-2